Evidence map›Paper›PMID 33560401›Full record

ArticleBlood advances2021

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

Adam Cuker, Eric K Tseng, Robby Nieuwlaat, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Jennifer Davila, Maria T DeSancho, David Diuguid, Daniel O Griffin and 35 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 232 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 11 pooled it
74.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

232 citing papers in PubMed, 11 syntheses or guidelines pooled it, 413 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Prophylactic anticoagulants for non-hospitalised people with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Anticoagulants for people hospitalised with COVID-19: a rapid reviewThe Cochrane database of systematic reviews · 2022
    Pooled it
  8. Guideline
  9. Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies.International journal of environmental research and public health · 2021
    Pooled it
  10. Pooled it
  11. Guideline
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

172 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 11 countries.

Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Eric K TsengSt. Michael's Hospital, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.
Robby NieuwlaatMichael G. DeGroote Cochrane Canada Centre.
Pantep AngchaisuksiriDivision of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clifton BlairUnion, NJ.
Kathryn DaneDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Jennifer DavilaChildren's Hospital at Montefiore, Division of Pediatric Hematology, Oncology, and Cellular Therapies, Albert Einstein College of Medicine, Bronx, NY.
Maria T DeSanchoDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY.
David DiuguidDepartment of Medicine, College of Physicians and Surgeons and.
Daniel O GriffinDivision of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY.
Susan R KahnDepartment of Medicine, McGill University, Montreal, QC, Canada.
Frederikus A KlokThrombosis and Hemostasis, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Alfred Ian LeeSection of Hematology, School of Medicine, Yale University, New Haven, CT.
Ignacio NeumannDepartment of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ashok PaiDivision of Hematology and Oncology, Kaiser Permanente, Oakland/Richmond, CA.
Menaka PaiDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Marc RighiniDivision of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Kristen M SanfilippoDepartment of Medicine, Washington University School of Medicine St. Louis, St. Louis, MO.
Deborah SiegalDepartment of Medicine and.
Mike SkaraCottage Grove, MN.
Kamshad TouriToronto, ON, Canada.
Elie A AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Imad Bou AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Mary BoulosMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Rana CharideClinical Research Institute, American University of Beirut, Beirut, Lebanon.
Matthew ChanDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Karin DearnessLibrary Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Andrea J DarziMichael G. DeGroote Cochrane Canada Centre.
Philipp KolbMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Luis E Colunga-LozanoDepartment of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Razan MansourOffice of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan.
Gian Paolo MorganoMichael G. DeGroote Cochrane Canada Centre.
Rami Z MorsiDepartment of Neurology, University of Chicago, Chicago, IL.
Atefeh NooriMichael G. DeGroote Cochrane Canada Centre.
Thomas PiggottDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Yuan QiuMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Yetiani RoldanDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Finn SchünemannMedizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
Adrienne StevensMichael G. DeGroote Cochrane Canada Centre.
Karla SoloMichael G. DeGroote Cochrane Canada Centre.
Matthew VentrescaMichael G. DeGroote Cochrane Canada Centre.
Wojtek WierciochMichael G. DeGroote Cochrane Canada Centre.
Reem A MustafaMichael G. DeGroote Cochrane Canada Centre.
Holger J SchünemannMichael G. DeGroote Cochrane Canada Centre.
Cochrane · CAMcMaster University · CAAmerican University of Beirut · LBImpact · CAUniversity of Freiburg · DEAlbert Einstein College of Medicine · USCottage Grove Community Medical Center · USJohns Hopkins Hospital · USKaiser Permanente Oakland Medical Center · USKing Hussein Cancer Center · JOLeiden University Medical Center · NLMahidol University · THMcGill University · CANewYork–Presbyterian Hospital · USPontificia Universidad Católica de Chile · CLRoyal College of Physicians · GBSt. Joseph’s Healthcare Hamilton · CASt. Michael's Hospital · CAUnitedHealth Group (United States) · USUniversidad de Guadalajara · MX

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE).

objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE.

methodsASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.

resultsThe panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE.

conclusionsThese recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.

Indexed as

AnticoagulantsCOVID-19EnoxaparinEvidence-Based MedicineGuidelines as TopicHumansSARS-CoV-2Societies, MedicalVenous ThromboembolismAnticoagulantsEnoxaparin

Identifiers

PMID33560401
PMCPMC7869684
OpenAlexW3128604271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.